Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Operations (Unaudited)

v3.21.2
Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Expenses    
Research and development $ 3,793 $ 1,357
General and administrative 2,178 1,534
Merger costs   500
In-process research and development 16,094 16,094
Operating Expenses (5,971) (19,485)
Other income (loss)    
Foreign exchange 4 1
Amortization of deferred loan costs   (27)
Interest, net 1 (7)
Other loss (income) 5 (33)
Net loss for the period (5,966) (19,518)
Computation of basic loss per share    
Net loss for the period (5,966) (19,518)
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance   (3,181)
Series A Preferred cash dividend (2) (2)
Series B Preferred stock dividend   (5)
Series C Preferred stock dividend (2,462)  
Net loss for the period attributable to common stockholders $ (8,430) $ (22,706)
Basic and fully diluted loss per share $ 0.25 $ (1.33)
Basic and fully diluted weighted average number of shares 34,281,000 17,106,000